Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway

被引:44
作者
Bruce, Ian [1 ]
Akhlaq, Mohammed [1 ]
Bloomfield, Graham C. [1 ]
Budd, Emma [1 ]
Cox, Brian [1 ]
Cuenoud, Bernard [1 ]
Finan, Peter [1 ]
Gedeck, Peter [1 ]
Hatto, Julia [1 ]
Hayler, Judy F. [1 ]
Head, Denise [1 ]
Keller, Thomas [1 ]
Kirman, Louise [1 ]
Leblanc, Catherine [1 ]
Le Grand, Darren [1 ]
McCarthy, Clive [1 ]
O'Connor, Desmond [1 ]
Owen, Charles [1 ]
Oza, Mrinalini S. [1 ]
Pilgrim, Gaynor [1 ]
Press, Nicola E. [1 ]
Sviridenko, Lilya [1 ]
Whitehead, Lewis [1 ]
机构
[1] Novartis Inst Biomed Res, Resp Dis Area, Horsham RH12 5AB, W Sussex, England
关键词
PI3-Kinase inhibitors; Pharmacological tools; Aminothiazoles; Parallel synthesis; Isoform selectivity; PHOSPHOINOSITIDE; 3-KINASE; P110-ALPHA; KINASES;
D O I
10.1016/j.bmcl.2012.07.042
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Using a parallel synthesis approach to target a non-conserved region of the PI3K catalytic domain a pan-PI3K inhibitor 1 was elaborated to provide alpha, delta and gamma isoform selective Class I PI3K inhibitors 21, 24, 26 and 27. The compounds had good cellular activity and were selective against protein kinases and other members of the PI3K superfamily including mTOR and DNA-PK. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5445 / 5450
页数:6
相关论文
共 30 条
[1]   PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways [J].
Abraham, RT .
DNA REPAIR, 2004, 3 (8-9) :883-887
[2]  
BLOOMFIELD GC, 2005, Patent No. 2005021519
[3]  
BRUCE I, 2008, Patent No. 2008000421
[4]  
BUDD E, 2007, Patent No. 2007068473
[5]   Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis [J].
Camps, M ;
Rückle, T ;
Ji, H ;
Ardissone, V ;
Rintelen, F ;
Shaw, J ;
Ferrandi, C ;
Chabert, C ;
Gillieron, C ;
Françon, B ;
Martin, T ;
Gretener, D ;
Perrin, D ;
Leroy, D ;
Vitte, PA ;
Hirsch, E ;
Wymann, MP ;
Cirillo, R ;
Schwarz, MK ;
Rommel, C .
NATURE MEDICINE, 2005, 11 (09) :936-943
[6]   Dual Inhibition of PI3Kα and mTOR as an Alternative Treatment for Kaposi's Sarcoma [J].
Chaisuparat, Risa ;
Hu, Jiadi ;
Jham, Bruno C. ;
Knight, Zachary A. ;
Shokat, Kevan M. ;
Montaner, Silvia .
CANCER RESEARCH, 2008, 68 (20) :8361-8368
[7]   Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils [J].
Condliffe, AM ;
Davidson, K ;
Anderson, KE ;
Ellson, CD ;
Crabbe, T ;
Okkenhaug, K ;
Vanhaesebroeck, B ;
Turner, M ;
Webb, L ;
Wymann, MP ;
Hirsch, E ;
Ruckle, T ;
Camps, M ;
Rommel, C ;
Jackson, SP ;
Chilvers, ER ;
Stephens, LR ;
Hawkins, PT .
BLOOD, 2005, 106 (04) :1432-1440
[8]  
Fairhurst R. H., 2009, World Pat, Patent No. [WO 2009/080705, 2009080705]
[9]   Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals [J].
Herman, Sarah E. M. ;
Gordon, Amber L. ;
Wagner, Amy J. ;
Heerema, Nyla A. ;
Zhao, Weiqiang ;
Flynn, Joseph M. ;
Jones, Jeffrey ;
Andritsos, Leslie ;
Puri, Kamal D. ;
Lannutti, Brian J. ;
Giese, Neill A. ;
Zhang, Xiaoli ;
Wei, Lai ;
Byrd, John C. ;
Johnson, Amy J. .
BLOOD, 2010, 116 (12) :2078-2088
[10]   Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase [J].
Hollick, Jonathan J. ;
Rigoreau, Laurent J. M. ;
Cano-Soumillac, Celine ;
Cockcroft, Xiaoling ;
Curtin, Nicola J. ;
Frigerio, Mark ;
Golding, Bernard T. ;
Guiard, Sophie ;
Hardcastle, Ian R. ;
Hickson, Ian ;
Hummersone, Marc G. ;
Menear, Keith A. ;
Martin, Niall M. B. ;
Matthews, Ian ;
Newell, David R. ;
Ord, Rachel ;
Richardson, Caroline J. ;
Smith, Graeme C. M. ;
Griffin, Roger J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (08) :1958-1972